sentence: Another Phase II trial enrolled 40 patients with SCCHN , receiving ONYX 015 at a dose of 20 particles via intratumoral injection for either 5 consecutive days ( standard , 30 ) or twice daily for two consecutive weeks ( hyperfractionated , ten ) during a 21-day cycle.59 Standard treatment resulted in 14 % partial to complete regression , while hyperfractionated treatment resulted in 10 % complete response , indicating that ONYX 015 was a safe treatment for SCCHN with evidence of modest antitumoral activity .